AstraZeneca, opens new tab said it will spend $2.5 billion on a research and development hub in Beijing, as the drugmaker scrambles to revive business in its second-biggest market after scandals including the arrest of its China president last year.
Chief Executive Pascal Soriot was in Beijing and met with the city's mayor to reveal the investment, along with two licensing deals with Chinese companies, and a joint venture with a third Chinese firm on vaccines, saying they all showed the company's commitment to the world's No. 2 economy.
"This $2.5 billion investment reflects our belief in the world-class life sciences ecosystem in Beijing, the extensive opportunities that exist for collaboration and access to talent, and our continued commitment to China," Soriot said in a statement.
The R&D centre "will partner with the cutting-edge biology and AI science in Beijing and be a critical part of our global efforts to bring innovative medicines to patients worldwide," Soriot said.
The centre in Beijing will be the company's second R&D site in China - a centre in Shanghai opened in 2024 - to match two such centres each that AstraZeneca has in the U.S. and Europe, respectively, a company spokesperson said.
The Chinese government has launched several investigations into AstraZeneca's executives and activities in the country, where the drugmaker has invested billions of dollars to build factories and license experimental drug candidates from Chinese biotech firms.
China accounted for about 12% of group revenue last year. The company, the UK's largest listed company worth 183 billion pounds ($236 billion) on the blue-chip FTSE 100 index, opens new tab, is the largest foreign drugmaker in China.
Soriot has often visited the country in recent years and praised the value of doing business there even when other multinationals complained of challenges or cited geopolitical tensions between China and Western countries as a risk for the pharma industry.
He is due to attend a flagship development conference in Beijing over the coming days where some are expected to meet Chinese President Xi Jinping.
The company put its former China head Leon Wang, who also led its international business as an executive vice president, on administrative leave following his detention by Chinese authorities in October, and overhauled its local management in China.
Soriot said at quarterly results last month that the company still does not know Wang's whereabouts. Its stock was hit hard by news of the probes in October 2024, but shares have since recovered as investors hope the impact could be minor.
A company spokesperson declined on Friday to comment on the status of the investigations.
The licensing agreements announced on Friday were with Chinese firms Harbour BioMed and Syneron Bio, for early-stage experimental medicines. The financial terms were not disclosed.
The deals were the latest of about a dozen AstraZeneca has signed with Chinese firms in the past several years - including on obesity drugs - worth a total of at least $9 billion, according to the company.
It is also launching a joint venture with another firm, BioKangtai, to develop, manufacture and commercialize vaccines for respiratory and other infectious diseases for patients in China and elsewhere. The site, in Beijing, will be the company's first vaccine manufacturing facility in the country.
The company on Friday also announced a partnership with state-run Beijing Cancer Hospital focused on data science and clinical development.
Kazakhstan's Minister of Foreign Affairs Yermek Kosherbayev met with his Chinese counterpart Foreign Minister Wang Yi in Beijing where the duo held al...
Israeli Prime Minister Benjamin Netanyahu has ordered strikes on Gaza after accusing Hamas of violating the ceasefire deal by firing on Israeli troops...
Inter Milan goalkeeper Josep Martínez was involved in a fatal road accident early Tuesday in Italy’s Como province after his vehicle struck a man i...
Three major companies announced on Tuesday that at least $80 billion worth of nuclear reactors will be built across the United States in partnership w...
The U.S. Department of War has said that it carried out three strikes in the eastern Pacific, killing 14 alleged narco-terrorists aboard four vessels,...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca is acquiring Belgium-based EsoBiotec for $1 billion to expand its cell therapy capabilities, with the deal set to close in the second quarter.
A small, silent object from another star is cutting through the Solar System. It’s real, not a film, and one scientist thinks it might be sending a message.
At least 69 people have died and almost 150 injured following a powerful 6.9-magnitude earthquake off the coast of Cebu City in the central Visayas region of the Philippines, officials said, making it one of the country’s deadliest disasters this year.
A tsunami threat was issued in Chile after a magnitude 7.8 earthquake struck the Drake Passage on Friday. The epicenter was located 135 miles south of Puerto Williams on the north coast of Navarino Island.
The war in Ukraine has reached a strategic impasse, and it seems that the conflict will not be solved by military means. This creates a path toward one of two alternatives: either a “frozen” phase that can last indefinitely or a quest for a durable political regulation.
A shooting in Nice, southeastern France, left two people dead and five injured on Friday, authorities said.
Russian President Vladimir Putin asked North Korean Foreign Minister Choe Son Hui during talks in the Kremlin on Monday to tell her country's leader Kim Jong Un that everything was "going to plan" in bilateral relations.
U.S. border czar says fentanyl should be considered a WMD.
U.S. states this week warned food aid recipients that their benefits may not be distributed in November if the federal government shutdown stretches into its fourth week.
The European Union is reportedly considering banning the use of ethanol as an active ingredient in biocidal products — including hand sanitisers — due to rising concerns about potential cancer risks, the Financial Times reported on Tuesday.
Johnson & Johnson (J&J) is facing its first lawsuits in the United Kingdom over claims that its talc-based products cause cancer, as it continues to battle tens of thousands of similar cases in the United States.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment